ABSTRACT - 597102 Disclosed herein is a kit comprising: (i) a nebulizer； (ii) a nebulizable composition which comprises: (a) a quaternary ammonium muscarinic receptor antagonist in a concentration based on the ammonium of between about 0.0005% and about 5% by weight； (b) a pharmacologically acceptable fluid； and (c) a pharmacologically acceptable preservative, wherein the pH of the composition is adjusted between about 2.0 to about 4.5 with an acid and the quaternary ammonium muscarinic receptor antagonist is dissolved in the fluid and optionally includes a pharmacologically acceptable complexing agent, stabilizer, a pharmacologically acceptable cosolvent, or other pharmacologically acceptable adjuvants and additives； and (iii) packaging material which includes instructions for the administration of the nebulizable composition to a patient in need of treatment or amelioration of one or more symptoms of disorders associated with bronchoconstriction； wherein the nebulizer is adapted to release the nebulized composition upon inhalation by the patient and ceases release of the nebulized composition when inhalation is stopped, the release of the nebulizable composition by the nebulizer results in minimal exposure of the nebulized composition to the body surface of the patient, and the loss of quaternary ammonium muscarinic receptor antagonists delivered to the mouth and lungs of the patient is less than 0.001 % w/w； wherein the quaternary ammonium muscarinic receptor antagonist is ipratropium, tiotropium, mixtures thereof and pharmaceutically acceptable derivatives thereof.
